Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2026 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizioAcceptable Use
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to Reports
Fundraising

Simon & Schuster

Simon & Schuster Raises $1B in Private

1230 Avenue of the Americas, New York, NY 10020January 1, 20242 min read
Employees
1400+

Simon & Schuster Raises $1B in Private


Simon & Schuster has successfully raised $1B in a Private at a $2B valuation led by Private.


Company Overview


Simon & Schuster is a Publishing company headquartered in 1230 Avenue of the Americas, New York, NY 10020, founded in 1924 with 1400+ employees.


Publishing company


Fundraising Details


  • Amount Raised: $1B
  • Round Type: Private
  • Valuation: $2B
  • Date: 2024-01-01
  • Investors: Private

About Simon & Schuster


Publishing company The company is positioned in the Publishing sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 1230 Avenue of the Americas, New York, NY 10020
  • Founded: 1924
  • Team Size: 1400+
  • Industry: Publishing

What This Means


This funding round demonstrates strong investor confidence in Simon & Schuster's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Publishing sector continues to attract significant investment as companies innovate to meet evolving market demands. Simon & Schuster's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $2B valuation marks an important milestone for Simon & Schuster, positioning the company among notable players in the Publishing industry.


Looking Ahead


With this new capital, Simon & Schuster is well-positioned to execute on its growth strategy and continue building innovative solutions in the Publishing space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Simon & Schuster, visit their headquarters at 1230 Avenue of the Americas, New York, NY 10020.

Company Info

Headquarters
1230 Avenue of the Americas, New York, NY 10020
Founded
1924
Team Size
1400+

Topics

Fundraising(2912)Private(347)PublishingSimon & Schuster

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free